Related Experiment Video
Updated: May 15, 2026
An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Peripherally-inserted central catheter-related fungemia due to hansenula polymorpha in a patient with pancreatic
1Division of Infectious Diseases, Department of Medicine, King Fahad Medical City, Riyadh, Saudi Arabia.
Abstract:
The methylotrophic yeast Hansenula polymorpha, used mainly as an industrial agent in the production of pharmaceuticals, has rarely been reported to cause disease. The case of a 47-year old Pilipino male with pancreatic cancer presented here is the second reported in the literature. Major risk factors for this infection included underlying malignancy, abdominal surgery and the use of a peripherally-inserted central catheter for total parenteral nutrition. He was successfully treated with a two-week's course of voriconazole.
Insights
Hansenula polymorpha, a yeast used in pharmaceuticals, rarely causes infections. This report details a second case of Hansenula polymorpha infection in a pancreatic cancer patient, successfully treated with voriconazole.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Clinical Case Reports
Background:
- Hansenula polymorpha is a methylotrophic yeast primarily utilized as an industrial agent in pharmaceutical production.
- This yeast is infrequently associated with human disease, with limited documented cases.
- Patients with underlying conditions and invasive devices are potentially at higher risk.
Purpose of the Study:
- To report a rare case of Hansenula polymorpha infection.
- To identify potential risk factors associated with this opportunistic infection.
- To highlight successful treatment strategies for Hansenula polymorpha infections.
Main Methods:
- A case study approach was employed.
- Patient history, clinical presentation, and treatment outcomes were reviewed.
- Literature review was conducted to compare with previously reported cases.
Main Results:
- A 47-year-old Filipino male with pancreatic cancer developed Hansenula polymorpha infection.
- Identified risk factors included underlying malignancy, recent abdominal surgery, and the use of a peripherally-inserted central catheter for total parenteral nutrition.
- The patient achieved a successful clinical outcome following a two-week course of voriconazole treatment.
Conclusions:
- Hansenula polymorpha represents a rare but potential opportunistic pathogen, particularly in immunocompromised individuals with specific risk factors.
- Early recognition and appropriate antifungal therapy, such as voriconazole, are crucial for successful management.
- Further research may be warranted to understand the full spectrum of Hansenula polymorpha pathogenicity and optimal treatment protocols.
